JP2023529691A5 - - Google Patents
Info
- Publication number
- JP2023529691A5 JP2023529691A5 JP2022575895A JP2022575895A JP2023529691A5 JP 2023529691 A5 JP2023529691 A5 JP 2023529691A5 JP 2022575895 A JP2022575895 A JP 2022575895A JP 2022575895 A JP2022575895 A JP 2022575895A JP 2023529691 A5 JP2023529691 A5 JP 2023529691A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- therapeutically effective
- approximately
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037469P | 2020-06-10 | 2020-06-10 | |
| US63/037,469 | 2020-06-10 | ||
| US202163195411P | 2021-06-01 | 2021-06-01 | |
| US63/195,411 | 2021-06-01 | ||
| PCT/US2021/036620 WO2021252630A1 (en) | 2020-06-10 | 2021-06-09 | Methods for treating or preventing chronic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529691A JP2023529691A (ja) | 2023-07-11 |
| JP2023529691A5 true JP2023529691A5 (enExample) | 2024-06-10 |
| JP7857235B2 JP7857235B2 (ja) | 2026-05-12 |
Family
ID=78846498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575895A Active JP7857235B2 (ja) | 2020-06-10 | 2021-06-09 | 慢性腎疾患を処置または防止するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230218563A1 (enExample) |
| EP (1) | EP4164624A4 (enExample) |
| JP (1) | JP7857235B2 (enExample) |
| KR (1) | KR20230024354A (enExample) |
| AU (1) | AU2021288679A1 (enExample) |
| CA (1) | CA3181902A1 (enExample) |
| IL (1) | IL298833A (enExample) |
| MX (1) | MX2022015678A (enExample) |
| TW (1) | TW202214228A (enExample) |
| WO (1) | WO2021252630A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| WO2020118114A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| US20250100988A1 (en) * | 2021-12-30 | 2025-03-27 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0913129A2 (pt) | 2008-05-22 | 2016-01-05 | Bristol Myers Squibb Co | método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| EP2968235B1 (en) | 2013-03-15 | 2017-09-13 | Janssen Pharmaceutica NV | Combination of canagliflozin and probenecid for the treatment of hyperuricemia |
| SG11201900405XA (en) | 2016-07-18 | 2019-02-27 | Arthrosi Therapeutics Inc | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |
| US20210130312A1 (en) * | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| BR112021006002A2 (pt) * | 2018-10-01 | 2021-06-29 | Astrazeneca Ab | composições para a redução de ácido úrico sérico |
| KR102946486B1 (ko) * | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| SG11202112562XA (en) * | 2019-05-14 | 2021-12-30 | Arthrosi Therapeutics Inc | Compound for treating gout or hyperuricemia |
-
2021
- 2021-06-09 AU AU2021288679A patent/AU2021288679A1/en active Pending
- 2021-06-09 IL IL298833A patent/IL298833A/en unknown
- 2021-06-09 EP EP21820911.2A patent/EP4164624A4/en active Pending
- 2021-06-09 MX MX2022015678A patent/MX2022015678A/es unknown
- 2021-06-09 TW TW110120962A patent/TW202214228A/zh unknown
- 2021-06-09 US US18/001,427 patent/US20230218563A1/en active Pending
- 2021-06-09 KR KR1020237000937A patent/KR20230024354A/ko active Pending
- 2021-06-09 CA CA3181902A patent/CA3181902A1/en active Pending
- 2021-06-09 JP JP2022575895A patent/JP7857235B2/ja active Active
- 2021-06-09 WO PCT/US2021/036620 patent/WO2021252630A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2086519B1 (en) | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors | |
| JP2012502015A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| WO2008101064A1 (en) | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist | |
| CN103429236A (zh) | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 | |
| KR20130097775A (ko) | 테오필린과 페북소스타트의 병용 치료 방법 | |
| Rashid | The efficacy and safety of PDE5 inhibitors | |
| JP2022510303A5 (enExample) | ||
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JP2020523334A5 (enExample) | ||
| JP2022529208A5 (enExample) | ||
| KR20090037347A (ko) | ＨＭＧ－ＣｏＡ 환원효소억제제와 담즙산을 포함하는 Ｃ형 간염 치료용 약학조성물 | |
| JP2020522560A5 (enExample) | ||
| JP2004519424A5 (ja) | インシュリン分泌促進剤およびＨＭＧ−Ｃｏ−Ａレダクターゼ阻害剤およびＡＣＥ阻害剤から選択される活性成分を含む組み合わせ | |
| Hiramoto et al. | Evidence-based analysis: postoperative gastric bleeding: etiology and prevention | |
| CN105434417A (zh) | 丹酚酸a在制备抗血管内膜增厚、抗血管成形术后和/或支架内再狭窄药物中的应用 | |
| CN110755432A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
| KR20250088666A (ko) | 손 습진의 치료 | |
| IL300406A (en) | Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection | |
| CN101229372A (zh) | 一种治疗高血压的药物组合物 | |
| Rubio et al. | Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil | |
| Caiati et al. | Cardiorenal syndrome triggered by slowly progressive drugs toxicity-induced renal failure along with minimal mitral disease: A case report | |
| Tissières et al. | Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension | |
| S. Hiremath et al. | Recent patents on oral combination drug delivery and formulations | |
| KR20220168172A (ko) | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물 |